| Neoplasms, Connective and Soft Tissue |
NCT01427582: YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access |
|
|
| No Longer Available | N/A | | US | Trabectedin, YONDELIS | University of Texas Southwestern Medical Center, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Soft Tissue Sarcoma | | | | |
NCT01646593: Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy |
|
|
| No Longer Available | N/A | | US | Regorafenib (BAY73-4506) | Bayer | Gastrointestinal Stromal Tumors | | | | |
NCT01613053: Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination |
|
|
| No Longer Available | N/A | | RoW | Glivec | Novartis Pharmaceuticals | Gastrointestinal Stromal Tumor | | | | |
NCT01689376: Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program) |
|
|
| No Longer Available | N/A | | RoW | Regorafenib (BAY73-4506) | Bayer | Gastrointestinal Stromal Tumors | | | | |
NCT00210665: A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment |
|
|
| No Longer Available | N/A | | US, Canada, RoW | Trabectedin | Janssen Research & Development, LLC | Sarcoma | | | | |
